Literature DB >> 15710327

A sumoylation site in PML/RARA is essential for leukemic transformation.

Jun Zhu1, Jun Zhou, Laurent Peres, Florence Riaucoux, Nicole Honoré, Scott Kogan, Hugues de Thé.   

Abstract

Pathogenesis of acute promyelocytic leukemia (APL) has been proposed to involve transcriptional repression through enhanced corepressors binding onto RARA moieties of PML/RARA homodimers. Unexpectedly, we show that the K160 sumoylation site in the PML moiety of PML/RARA is required for efficient immortalization/differentiation arrest ex vivo, implying that RARA homodimerization is insufficient to fully immortalize primary hematopoietic progenitor cells. Similarly, PML/RARAK160R transgenic mice develop myeloproliferative syndromes, but never APL. The Daxx repressor no longer binds PML/RARAK160R, but fusion of these two proteins restores the differentiation block ex vivo. Thus, transcriptional repression dependent on a specific sumoylation site in PML is critical for the APL phenotype, while forced RARA dimerization could control expansion of the myeloid compartment.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15710327     DOI: 10.1016/j.ccr.2005.01.005

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  52 in total

1.  Eradication of acute promyelocytic leukemia-initiating cells by PML/RARA-targeting.

Authors:  Rihab Nasr; Hugues de Thé
Journal:  Int J Hematol       Date:  2010-05-11       Impact factor: 2.490

2.  The SUMO E3-ligase PIAS1 regulates the tumor suppressor PML and its oncogenic counterpart PML-RARA.

Authors:  Andrea Rabellino; Brandon Carter; Georgia Konstantinidou; Shwu-Yuan Wu; Alessandro Rimessi; Lauren A Byers; John V Heymach; Luc Girard; Cheng-Ming Chiang; Julie Teruya-Feldstein; Pier Paolo Scaglioni
Journal:  Cancer Res       Date:  2012-03-09       Impact factor: 12.701

3.  Dimerization-induced corepressor binding and relaxed DNA-binding specificity are critical for PML/RARA-induced immortalization.

Authors:  Jun Zhou; Laurent Pérès; Nicole Honoré; Rihab Nasr; Jun Zhu; Hugues de Thé
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-06       Impact factor: 11.205

4.  Chromatin modifications induced by PML-RARalpha repress critical targets in leukemogenesis as analyzed by ChIP-Chip.

Authors:  Claudia Hoemme; Abdul Peerzada; Gerhard Behre; Yipeng Wang; Michael McClelland; Kay Nieselt; Matthias Zschunke; Christine Disselhoff; Shuchi Agrawal; Fabienne Isken; Nicola Tidow; Wolfgang E Berdel; Hubert Serve; Carsten Müller-Tidow
Journal:  Blood       Date:  2007-11-16       Impact factor: 22.113

Review 5.  PML nuclear bodies: assembly and oxidative stress-sensitive sumoylation.

Authors:  Umut Sahin; Hugues de Thé; Valérie Lallemand-Breitenbach
Journal:  Nucleus       Date:  2014       Impact factor: 4.197

6.  Targeting pseudokinase TRIB3 brings about a new therapeutic option for acute promyelocytic leukemia.

Authors:  Ke Li; Feng Wang; Zhuo-Wei Hu
Journal:  Mol Cell Oncol       Date:  2017-06-16

Review 7.  Harnessing preclinical mouse models to inform human clinical cancer trials.

Authors:  David H Gutmann; Kim Hunter-Schaedle; Kevin M Shannon
Journal:  J Clin Invest       Date:  2006-04       Impact factor: 14.808

Review 8.  How animal models of leukaemias have already benefited patients.

Authors:  Julien Ablain; Rihab Nasr; Jun Zhu; Ali Bazarbachi; Valérie Lallemand-Breittenbach; Hugues de Thé
Journal:  Mol Oncol       Date:  2013-02-11       Impact factor: 6.603

9.  ZYH005, a novel DNA intercalator, overcomes all-trans retinoic acid resistance in acute promyelocytic leukemia.

Authors:  Qingyi Tong; Huijuan You; Xintao Chen; Kongchao Wang; Weiguang Sun; Yufeng Pei; Xiaodan Zhao; Ming Yuan; Hucheng Zhu; Zengwei Luo; Yonghui Zhang
Journal:  Nucleic Acids Res       Date:  2018-04-20       Impact factor: 16.971

10.  SUMOylation regulates nuclear localization of Krüppel-like factor 5.

Authors:  James X Du; Agnieszka B Bialkowska; Beth B McConnell; Vincent W Yang
Journal:  J Biol Chem       Date:  2008-09-09       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.